Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2023-03-17 00:00:00 ET · period of report 2023-03-14 · accession 0001209191-23-019893 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-17 | 2023-03-14 | DFTX | Wernli Miri Halperin | Executive Pres, Dir | A - Grant | $0.00 | +100.0K | 1.38M | +8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-03-14 | A | A | 100,000 | $0.00 | 1,375,000 | D | — | — | (F1) These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 14, 2023, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date. |